Drawing for MEDICAL ONCOLOGY ASSOCIATES OF TOPEKA

USPTO serial 78426032

MEDICAL ONCOLOGY ASSOCIATES OF TOPEKA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
SAPPENFIELD, ANN
Law office
TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with MEDICAL ONCOLOGY ASSOCIATES OF TOPEKA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
044treatment of diseases of the blood and/or lymphatic system; treatment of cancer; massage therapy as it applies to the treatment of cancer and treatment of the side effects of cancer therapies; nutritional recommendations as related to treatment of cancer or diseases of the blood or treatment of the side effects of cancer medicationsACTIVEJun 1, 2004

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Sep 7, 2005MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Sep 7, 2005ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 8, 2005TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 9, 2005GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 9, 2005IUAAUSE AMENDMENT ACCEPTED—
Feb 9, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 31, 2004DOCKASSIGNED TO EXAMINER—
Dec 3, 2004AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Dec 3, 2004ALIEASSIGNED TO LIE—
Nov 29, 2004IUAFUSE AMENDMENT FILED—
Nov 29, 2004AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Nov 29, 2004EAAUTEAS AMENDMENT OF USE RECEIVED—
Jun 9, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 2, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance